Elevated circulating levels of soluble CD-40 ligand in haemodialysis patients with symptomatic coronary heart disease

Nephrology

Volumn 13, Issue 8, 2008, Pages 677-683

  Lim, Paik Seong ^a,b,c   Wu, Ming Ying ^a   Chien, Shiaw Wen ^a   Wu, Tsai Kun ^a   Liu, Chia Shan ^a   Hu, Chuen Yuh ^a   Chang, Hui Chen ^a   Pai, Mei An Tsai ^a  

^a TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

^b PROVIDENCE UNIVERSITY   (Taiwan)

^c NONE   (Taiwan)

Author keywords

Coronary heart disease; Haemodialysis; Inflammation; Soluble CD40 ligand

Indexed keywords

3 NITROTYROSINE; C REACTIVE PROTEIN; CD40 LIGAND; MALONALDEHYDE; SOLUBLE CD40 LIGAND; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CARBONYLATION; PROTEIN FUNCTION;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CD40 LIGAND; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; KIDNEY FAILURE, CHRONIC; LIPIDS; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; PILOT PROJECTS; PROTEIN CARBONYLATION; RENAL DIALYSIS; TYROSINE; UP-REGULATION; VASCULAR CELL ADHESION MOLECULE-1;

EID: 58149136241     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2008.00999.x     Document Type: Article

References (44)

1. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 1999 340 : 115 26.
2. Libby P. Inflammation in atherosclerosis. Nature 2002 420 : 868 74.
3. Hollenbaugh D, Grosmaire LS, Kullas CD et al. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: Expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J 1992 11 : 4313 21.
4. Clark LB, Foy TM, Noelle RJ. CD40 and its ligand. Adv. Immunol. 1996 63 : 43 78.
5. Grewal IS, Flavell RA. The CD40 ligand. At the center of the immune universe? Immunol. Res. 1997 16 : 59 70.
6. Henn V, Slupsky JR, Grafe M et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998 391 : 591 4.
7. May AE, Kalsch T, Massberg S, Herouy Y, Schmidt R, Gawaz M. Engagement of glycoprotein IIb/IIIa on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation 2002 106 : 2111 7.
8. Gauchat JF, Aubry JP, Mazzei G et al. Human CD40-ligand: Molecular cloning, cellular distribution and regulation of expression by factors controlling IgE production. FEBS Lett. 1993 315 : 259 66.
9. Schönbeck U, Libby P. The CD40/CD154 receptor/ligand. Cell. Mol. Life Sci. 2001 58 : 4 43.
10. Laman JD, de Smet BJ, Schoneveld A. CD40-CD40L interactions in atherosclerosis. Immunol. Today 1997 18 : 272 7.
11. Mach F, Schonbeck U, Libby P. CD40 signaling in vascular cells: A key role in atherosclerosis. Atherosclerosis 1998 137 : S89 95.
12. Varo N, de Lemos JA, Libby P et al. Soluble CD40L: Risk prediction after acute coronary syndromes. Circulation 2003 108 : 1049 52.
13. Heeschen C, Dimmeler S, Hamm CW et al. 40 ligand in acute coronary syndromes. N. Engl. J. Med. 2003 348 : 1104 11.
14. Ter Steege JCA, Koster-Kamphuis L, Van Straaten E, Forget P, Buurman WA. Nitrotyrosine in plasma of celiac disease patients as detected by a new sandwich ELISA. Free Radical. Biol. Med. 1998 25 : 953 63.
15. Reznick AZ, Packer L. Oxidative damage to proteins: Spectrophotometric method for carbonyl assay. Methods Enzymol. 1994 233 : 357 63.
16. Wong SH, Knight JA, Hopfer SM, Zaharia O, Leach CN Jr., Sunderman FW Jr. Lipoperoxides in plasma as measured by liquid-chromatographic separation of malondialdehyde-thiobarbituric acid adduct. Clin. Chem. 1987 33 : 214 20.
17. Schönbeck U, Libby P. CD40 signaling and plaque instability. Circ. Res. 2001 89 : 1092 103.
18. Kiener PA, Moran-Davis P, Rankin BM, Wahl AF, Aruffo A, Hollenbaugh D. Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J. Immunol. 1995 155 : 4917 25.
19. Aukrust P, Muller F, Ueland T et al. Enhanced levels of soluble and membrane bound CD40 ligand in patients with unstable angina: Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999 100 : 614 20.
20. Peng DQ, Zhao SP, Li YF, Li J, Zhou HN. Elevated soluble CD40 ligand is related to the endothelial adhesion molecules in patients with acute coronary syndrome. Clin. Chim. Acta. 2002 319 : 19 26.
21. Cipollone F, Mezzetti A, Porreca E et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: Effects of statin therapy. Circulation 2002 106 : 399 402.
22. Semb AG, van Wissen S, Ueland T et al. Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: Downregulatory effect of statin therapy. J. Am. Coll. Cardiol. 2003 41 : 275 9.
23. Marx N, Imhof A, Froehlich J et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type-2 diabetes and coronary artery disease. Circulation 2003 107 : 1954 7.
24. Varo N, Vicent D, Libby P et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: A novel target of thiazolidinediones. Circulation 2003 107 : 2664 9.
25. Schwabe RF, Engelmann H, Hess S, Fricke H. Soluble CD40 in the serum of healthy donors, patients with chronic renal failure, hemodialysis and chronic ambulatory peritoneal dialysis (CAPD) patients. Clin. Exp. Immunol. 1999 117 : 153 8.
26. Dechanet J, Grosset C, Taupin JL et al. CD40 ligand stimulates proinflammatory cytokine production by human endothelial cells. J. Immunol. 1997 159 : 5640 7.
27. Wagner AH, Guldenzoph B, Lienenluke B, Hecker M. CD154/CD40-mediated expression of CD154 in endothelial cells: Consequences for endothelial cell-monocyte interaction. Arterioscler. Thromb. Vasc. Biol. 2004 24 : 715 20.
28. Tayebjee MH, Lip GY, Tan KT, Patel JV, Hughes EA, MacFadyen RJ. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. Am. J. Cardiol. 2005 96 : 339 45.
29. Tanaka T, Kuroiwa T, Ikeuchi H et al. Human platelets stimulate mesangial cells to produce monocyte chemoattractant protein-1 via the CD40/CD40 ligand pathway and may amplify glomerular injury. J. Am. Soc. Nephrol. 2002 13 : 2488 96.
30. Spittle MA, Hoenich NA, Handelman GJ, Adhikarla R, Homel P, Levin NW. Oxidative stress and inflammation in hemodialysis patients. Am. J. Kidney Dis. 2001 38 : 1408 13.
31. Himmelfarb J, Hakim RM. Oxidative stress in uremia. Curr. Opin. Nephrol. Hyperten. 2003 12 : 593 8.
32. Grisham MB, Granger DN, Lefer DJ. Modulation of leukocyte- endothelial interactions by reactive metabolites of oxygen and nitrogen: Relevance to ischemic heart disease. Free Radic. Biol. Med. 1998 25 : 404 33.
33. Cooper D, Stokes KY, Tailor A, Granger DN. Oxidative stress promotes blood cell-endothelial cell interactions in the microcirculation. Cardiovasc. Toxicol. 2002 2 : 165 80.
34. Lim HS, Blann AD, Lip GYH. Soluble CD40 ligand, soluble P-Selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation 2004 109 : 2524 8.
35. Si C, Varghese S, Vitseva O, Tanriverdi K, Freedman JE. CD40 ligand influences platelet release of reactive oxygen intermediates. Arterioscler. Thromb. Vasc. Biol. 2005 25 : 2428 34.
36. Sirolli V, Strizzi L, Stante SD, Robuffo I, Procopio A, Bonomini M. Platelet activation and platelet-erythrocyte aggregates in end-stage renal disease patients on hemodialysis. Thromb. Hemost. 2001 86 : 834 9.
37. Bonomini M, Reale M, Santarelli P, Stuard S, Settefrati N, Albertazzi A. Serum levels of soluble adhesion molecules in chronic renal failure and dialysis patients. Nephron 1998 79 : 399 407.
38. FitzGerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N. Engl. J. Med. 1986 315 : 983 9.
39. Danesh J, Collins R, Appleby P, Peto R. Fibrinogen, C-reactive protein, albumin or white cell count: Meta-analyses of prospective studies of coronary heart disease. JAMA 1998 279 : 1477 82.
40. Gillum RF, Makuc DM. Serum albumin, coronary heart disease, and death. Am. Heart J. 1992 123 : 507 13.
41. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999 55 : 648 58.
42. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am. J. Kidney Dis. 2000 35 : 469 76.
43. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N et al. Revisiting mortality predictability of serum albumin in the dialysis population: Time dependency, longitudinal changes and population-attributable fraction. Nephrol. Dial. Transplant. 2005 20 : 1880 8.
44. Joki N, Hase H, Tanaka Y et al. Relationship between serum albumin level before initiating hemodialysis and angiographic severity of coronary atherosclerosis in end-stage renal disease patients. Nephrol. Dial. Transplant. 2006 21 : 1633 9.